China SXT Pharmaceuticals
SXTC
2 hedge funds and large institutions have $32.3K invested in China SXT Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
51% less capital invested
Capital invested by funds: $65.5K → $32.3K (-$33.2K)
67% less funds holding
Funds holding: 6 → 2 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$11K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.02K |
| 3 |
Renaissance Technologies
New York
|
-$6.82K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Acadian Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
|
TSS
2
Two Sigma Securities
New York
| $4.83K | – | – | – |
|
|
CAN
3
Cetera Advisor Networks
El Segundo,
California
| $2.45K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $2K | -$6.82K | -1 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$7.02K | -1 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$5.1K | -1 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$11K | -1 | Closed |
|
SXTC Hedge Fund Activity: Q2 2023 in Review
2 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2023, worth a combined $32.3K — down 51% from $65.5K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SXTC and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Virtu Financial, exiting entirely with an estimated $11K sold.
- 2 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q2 2023, down from 6 in Q1 2023.
- Funds reported $32.3K of China SXT Pharmaceuticals stock for Q2 2023, down 51% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest China SXT Pharmaceuticals seller in Q2 2023 was Virtu Financial, an estimated $11K sold.
Based on aggregated 13F filings for Q2 2023.